OncoCyte Corporation (OCX)

$0.852

-0.05 (-5.30%)
Rating:
Recommendation:
Neutral
Symbol OCX
Price $0.852
Beta 1.875
Volume Avg. 0.67M
Market Cap 100.973M
Shares () -
52 Week Range 0.836-6.25
1y Target Est -
DCF Unlevered OCX DCF ->
DCF Levered OCX LDCF ->
ROE -86.95% Strong Sell
ROA -48.18% Strong Sell
Operating Margin -
Debt / Equity 156.77% Buy
P/E -
P/B 1.38 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest OCX news


Mr. Ronald A. Andrews Jr.
Healthcare
Biotechnology
NASDAQ Global Market

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.